Related references
Note: Only part of the references are listed.Control of hyperparathyroidism with the intravenous calcimimetic etelcalcetide in dialysis patients adherent and non-adherent to oral calcimimetics
Maria Dolores Arenas et al.
CLINICAL KIDNEY JOURNAL (2021)
One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism
David A. Bushinsky et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2020)
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis
Bradley A. Warady et al.
PEDIATRIC NEPHROLOGY (2019)
The global burden of kidney disease and the sustainable development goals
Valerie A. Luyckx et al.
BULLETIN OF THE WORLD HEALTH ORGANIZATION (2018)
Clinical Pharmacokinetics and Pharmacodynamics of Etelcalcetide, a Novel Calcimimetic for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis
Benjamin Wu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Population Pharmacokinetic and Pharmacodynamic Modeling of Etelcalcetide in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis
Ping Chen et al.
CLINICAL PHARMACOKINETICS (2018)
Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism Two Randomized Clinical Trials
Geoffrey A. Block et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism A Randomized Clinical Trial
Geoffrey A. Block et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Clinical immunogenicity of the D-amino acid peptide therapeutic etelcalcetide: Method development challenges and anti-drug antibody clinical impact assessments
Mark A. Kroenke et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2017)
Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters
Markus Ketteler et al.
KIDNEY INTERNATIONAL (2017)
Clinical practice recommendations for treatment with active vitamin D analogues in children with chronic kidney disease Stages 2-5 and on dialysis
Rukshana Shroff et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2017)
A Single-and Multiple-Dose, Multicenter Study of Etelcalcetide in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism
Keitaro Yokoyama et al.
KIDNEY INTERNATIONAL REPORTS (2017)
Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism
Jordi Bover et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis
Nathan R. Hill et al.
PLOS ONE (2016)
Chronic kidney disease in children
Francesca Becherucci et al.
CLINICAL KIDNEY JOURNAL (2016)
Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial
Sharon M. Moe et al.
CIRCULATION (2015)
A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM)
James B. Wetmore et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
Population Pharmacokinetics Analysis of AMG 416, an Allosteric Activator of the Calcium-Sensing Receptor, in Subjects With Secondary Hyperparathyroidism Receiving Hemodialysis
Ping Chen et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Cinacalcet in Pediatric and Adolescent Chronic Kidney Disease A Single-Center Experience
Abdulla A. Alharthi et al.
MEDICINE (2015)
AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients
Kevin J. Martin et al.
KIDNEY INTERNATIONAL (2014)
Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism
Katherine Wesseling-Perry et al.
KIDNEY INTERNATIONAL (2011)
Mineral and bone disorders in children with chronic kidney disease
Claus Peter Schmitt et al.
NATURE REVIEWS NEPHROLOGY (2011)
Long-term control of parathyroid hormone and calcium-phosphate metabolism after parathyroidectomy in children with chronic kidney disease
Betti Schaefer et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2010)
Clinical and economic outcomes of thyroid and parathyroid surgery in children
Julie Ann Sosa et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis
WG Goodman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)